Clinical trial

Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' 10-valent…

NCT00334334 · GlaxoSmithKline, Industry · Completed

Key facts

NCT number NCT00334334
Title Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate Vaccine.
Official title To Assess Safety, Reactogenicity and Immunogenicity of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine, When Co-administered With DTPa-combined Vaccines and MenC or Hib-MenC Vaccines During the First 6 Months of Age.
Lead sponsor GlaxoSmithKline, Industry
Status Completed
Phase Phase 3
Study type Interventional
Conditions Infections, Streptococcal
Intervention type Biological
Interventions Pneumococcal (vaccine)
Enrollment 1,572
Start date Jun 1, 2006
Primary completion Jul 1, 2007
Completion Aug 1, 2007
First posted Jun 7, 2006
Last update posted Nov 4, 2016
Countries Germany, Poland, Spain

At a glance

  • 10–99 Study sites
  • No Results posted
  • None Linked FDA submissions

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About ClinicalTrials.gov studies

ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.

Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date:

Browse all ClinicalTrials.gov studies